Sandoz’ Neulasta Biosimilar Filing Joins Another Pending At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The Novartis drug unit said the biosimilar pegfilgrastim application was accepted by FDA, positioning the 351(k) filing for action in mid-2016.